CN106459183B - 人源化百日咳抗体及其用途 - Google Patents

人源化百日咳抗体及其用途 Download PDF

Info

Publication number
CN106459183B
CN106459183B CN201580017463.1A CN201580017463A CN106459183B CN 106459183 B CN106459183 B CN 106459183B CN 201580017463 A CN201580017463 A CN 201580017463A CN 106459183 B CN106459183 B CN 106459183B
Authority
CN
China
Prior art keywords
antibody
seq
humanized
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580017463.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459183A (zh
Inventor
J·梅纳德
A·阮
E·帕德兰
E·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthetic Biological Products Co
University of Texas System
Original Assignee
Synthetic Biological Products Co
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biological Products Co, University of Texas System filed Critical Synthetic Biological Products Co
Publication of CN106459183A publication Critical patent/CN106459183A/zh
Application granted granted Critical
Publication of CN106459183B publication Critical patent/CN106459183B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580017463.1A 2014-03-31 2015-03-31 人源化百日咳抗体及其用途 Active CN106459183B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973141P 2014-03-31 2014-03-31
US61/973,141 2014-03-31
US201462046403P 2014-09-05 2014-09-05
US62/046,403 2014-09-05
PCT/US2015/023715 WO2015153685A1 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN106459183A CN106459183A (zh) 2017-02-22
CN106459183B true CN106459183B (zh) 2020-05-19

Family

ID=54241237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580017463.1A Active CN106459183B (zh) 2014-03-31 2015-03-31 人源化百日咳抗体及其用途

Country Status (8)

Country Link
US (3) US9512204B2 (enExample)
EP (1) EP3126385B1 (enExample)
JP (1) JP6588922B2 (enExample)
CN (1) CN106459183B (enExample)
AU (1) AU2015240834B2 (enExample)
CA (1) CA2941152C (enExample)
ES (1) ES2755957T3 (enExample)
WO (1) WO2015153685A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752396A1 (en) * 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof
MD20160130A2 (ro) * 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US20210332112A1 (en) * 2016-08-15 2021-10-28 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
AU2018351072B9 (en) 2017-10-20 2024-09-05 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
EP3995510A4 (en) * 2019-07-01 2023-11-08 Suzhou Alphamab Co., Ltd PERTUSSIS TOXIN BINDING PROTEIN
WO2024237730A1 (ko) * 2023-05-18 2024-11-21 한국과학기술연구원 항-엔도글린 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
WO2014160098A3 (en) * 2013-03-13 2014-11-20 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223529B (it) 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7417133B2 (en) * 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
CA2752396A1 (en) 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
WO2014160098A3 (en) * 2013-03-13 2014-11-20 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Characterization of a Key Neutralizing Epitope on Pertussis Toxin Recognized by Monoclonal Antibody 1B7;Jamie N. Sutherland等;《Biochemistry》;20090911;第50卷(第48期);第11982-11993页 *
Construction and Characterization of Single-Chain Variable Fragment Antibodies Directed against the Bordetella pertussis Surface Adhesins Filamentous Hemagglutinin and Pertactin;Ahmad H. Hussein等;《INFECTION AND IMMUNITY》;20070827;第75卷(第11期);第5476-5482页 *

Also Published As

Publication number Publication date
ES2755957T3 (es) 2020-04-24
US20170066816A1 (en) 2017-03-09
EP3126385A4 (en) 2018-02-21
JP2017511140A (ja) 2017-04-20
US9512204B2 (en) 2016-12-06
US20150353628A1 (en) 2015-12-10
AU2015240834B2 (en) 2020-02-27
CA2941152C (en) 2023-09-19
CA2941152A1 (en) 2015-10-08
US10035846B2 (en) 2018-07-31
EP3126385B1 (en) 2019-09-18
JP6588922B2 (ja) 2019-10-09
AU2015240834A1 (en) 2016-09-15
US20180362621A1 (en) 2018-12-20
US10526400B2 (en) 2020-01-07
CN106459183A (zh) 2017-02-22
WO2015153685A1 (en) 2015-10-08
EP3126385A1 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
CN106459183B (zh) 人源化百日咳抗体及其用途
CN110418803B (zh) 抗rsv单克隆抗体配制品
CN106102837B (zh) 双特异性hiv-1-中和抗体
BR112021008778A2 (pt) Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
JP2015522524A (ja) 抗体製剤
US8617548B2 (en) Methods of preventing or treating anthrax using anti-anthrax antibodies
CA3115708A1 (en) Formulations of anti-rsv antibodies and methods of use thereof
CA3149209A1 (en) Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors
JP2018531980A (ja) 抗ｄ因子抗体製剤
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
US20210332112A1 (en) Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) Bispecific pertussis antibodies
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
WO2021139687A1 (zh) 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用
US20160106837A1 (en) Combination of cd37 antibodies with chlorambucil
JP7315259B2 (ja) 百日咳毒素結合タンパク質
EP4410836A1 (en) Anti-cd47 antibody for combined treatment of blood tumor
WO2025056005A1 (zh) 抗tim-3抗体的药物组合物及用途
JP2025530992A (ja) 形質細胞様樹状細胞の枯渇および阻害
WO2025056014A1 (zh) 包含抗pd-1抗体和第二抗体的药物组合物
CN118987198A (zh) 抗tslp抗体治疗慢性鼻窦炎的方法
NZ744721A (en) Treatment for rheumatoid arthritis
GB2496854A (en) Anti-VEEV antibodies and their use in prophylaxis or treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant